Telmisartan Teva Pharma 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
IAIN/0024 
B.II.e.5.a.1 - Change in pack size of the finished 
08/10/2021 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
N/0023 
Minor change in labelling or package leaflet not 
17/09/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0022 
A.7 - Administrative change - Deletion of 
12/01/2021 
Annex II and 
manufacturing sites 
PL 
IA/0021 
B.II.d.2.a - Change in test procedure for the finished 
31/07/2019 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/06/2019 
25/07/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0019/G 
This was an application for a group of variations. 
03/05/2019 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0017 
B.II.d.2.a - Change in test procedure for the finished 
08/07/2016 
n/a 
product - Minor changes to an approved test 
procedure 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0016 
A.7 - Administrative change - Deletion of 
14/06/2016 
n/a 
manufacturing sites 
R/0014 
Renewal of the marketing authorisation. 
28/04/2016 
09/06/2016 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Telmisartan Teva Pharma in the approved indication 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
IA/0015/G 
This was an application for a group of variations. 
19/04/2016 
09/06/2016 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
T/0012 
Transfer of Marketing Authorisation 
22/01/2015 
10/02/2015 
SmPC, 
Labelling and 
PL 
A31/0006 
On 17 April 2013, further to the emergence of new 
22/05/2014 
04/09/2014 
SmPC and PL 
For further information please refer to the Renin-
evidence from the scientific literature on dual RAS 
blockade therapy and given the seriousness of the 
identified safety concerns, the Italian Medicines 
Agency (AIFA) initiated a review under Article 31 of 
Council Directive 2001/83/EC, requesting the 
Pharmacovigilance Risk Assessment Committee 
(PRAC) to issue a recommendation on the benefit-
angiotensin-system (RAS)-acting agents Article 31 referral 
- Assessment report. 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
risk of dual RAS blockade therapy through the 
combined use of angiotensin-converting enzyme 
inhibitors (ACE-inhibitors), angiotensin II receptor 
blockers (ARBs) or aliskiren and to determine 
whether any regulatory measures should be taken on 
the marketing authorisations of the products 
involved in this procedure. 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/04/2014 
06/06/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/2882/
Periodic Safety Update EU Single assessment - 
07/11/2013 
n/a 
PRAC Recommendation - maintenance 
201304 
hydrochlorothiazide / telmisartan, telmisartan 
IB/0008/G 
This was an application for a group of variations. 
09/10/2013 
06/06/2014 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0009 
B.III.1.a.2 - Submission of a new/updated or 
27/09/2013 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0007/G 
This was an application for a group of variations. 
04/09/2013 
n/a 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IAIN/0005/G 
This was an application for a group of variations. 
05/06/2013 
06/06/2014 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
IA/0004/G 
This was an application for a group of variations. 
11/03/2013 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0003/G 
This was an application for a group of variations. 
26/07/2012 
29/10/2012 
SmPC, 
Labelling and 
PL 
Update of section 4.4 of the SmPC to include a 
warning for diabetic patients when treated with 
insulin or oral antidiabetics and to include a warning 
on RAAS blockage in patients with uncontrolled blood 
pressure, and update to section 4.8 of the SmPC to 
include "cough", "somnolence" and "interstitial lung 
disease" as new ADR and consequential changes to 
section 4 of the Package Leaflet. These changes are 
implemented following approval of variation 
EMEA/H/C/000209/WS/0220 for Micardis. 
Update of sections 4.1, 4.2, 4.8 and 5.1 of the SmPC 
and consequently sections 1, 3 and 4 of the Package 
Leaflet to add indication of cardiovascular prevention 
in line with the indications registered for the 
reference product Micardis. This indication was 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
registered for the reference product Micardis via 
variation EMEA/H/C/000209/II/0073. 
In addition the MAH has aligned the Annexes with 
version 8 of the QRD template and updated the list 
of local representatives in the Package Leaflet for 
Austria, Estonia, Finland, Germany, Italy, Ireland, 
Norway and United Kingdom. 
Furthermore, minor amendments have been 
introduced in some languages to keep the Product 
Information in line with the originator product. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0001/G 
This was an application for a group of variations. 
09/07/2012 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the currently approved batch 
size 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
B.I.c.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Other variation 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IAIN/0002/G 
This was an application for a group of variations. 
16/05/2012 
29/10/2012 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
